Your browser doesn't support javascript.
loading
HRF20/CD59 complement regulatory protein expression is phenotype-dependent and inducible by the hypomethylating agent 5-azacytidine on Burkitt's lymphoma cell lines.
Kuraya, M; Minarovits, J; Okada, H; Klein, E.
  • Kuraya M; Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden.
Immunol Lett ; 37(1): 35-9, 1993 Jul.
Article en En | MEDLINE | ID: mdl-7693582
ABSTRACT
We studied the expression of the 20-kDa homologous restriction factor (CD59/HRF20), a complement regulatory protein, on two subsets of blood derived B cells and on Burkitt's lymphoma lines. Both low-density (activated) and high-density (resting) B cell populations expressed high levels of CD59. CD59 was detectable, however, only on a minority of cells or not at all on three Epstein-Barr virus (EBV)-negative BL lines (BL41, BL28 and DG75) and on clones of an EBV-positive BL line (Mutu) that phenotypically resembled resting B lymphocytes. On the other hand, CD59 was detected at high or medium levels on Mutu cells which had a lymphoblastoid cell-like phenotype. Expression of CD59 was upregulated by 5-azacytidine, a drug inhibiting cytosine methylation, on CD59-negative cell lines. Induction was accompanied by a partial hypomethylation in the 5' region of CD59 coding sequences.
Asunto(s)
Search on Google
Banco de datos: MEDLINE Asunto principal: Azacitidina / Glicoproteínas de Membrana / Antígenos CD / Linfoma de Burkitt Límite: Humans Idioma: En Año: 1993 Tipo del documento: Article
Search on Google
Banco de datos: MEDLINE Asunto principal: Azacitidina / Glicoproteínas de Membrana / Antígenos CD / Linfoma de Burkitt Límite: Humans Idioma: En Año: 1993 Tipo del documento: Article